Clin2
NCT06529822Possibly a fitRecruiting

Personalized cancer vaccine for solid tumors with MRD

Muscle-Invasive Bladder CarcinomaGastroesophageal AdenocarcinomaMelanomaNon-small Cell Lung Cancer

Treatments studied

Part of Cancer, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.

This trial tests a personalized cancer vaccine for people with certain cancers (bladder, stomach/esophagus, melanoma, or lung) who have no visible cancer after surgery but still have tiny bits of cancer DNA in their blood (called MRD). The vaccine is designed to train your immune system to attack any remaining cancer cells.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
64 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have had surgery to remove your cancer, and scans show no remaining tumor.
  • A blood test (Signatera) shows small amounts of cancer DNA (MRD positive).
  • Your cancer is one of these types: bladder/upper tract, stomach/esophagus, melanoma, or non-small cell lung cancer, at specific stages.
  • You are willing to use contraception during and for 5 months after treatment (if applicable).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05264974Recruiting· Phase 1
Personal tumor vaccine for melanoma and soft tissue sarcoma

This trial tests a personalized vaccine made from your own tumor tissue. The goal is to help your immune system fight cancer and to improve the response to PD-1 inhibitor therapy.

Gainesville, Florida
NCT05269381Recruiting· Phase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors

This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.

Jacksonville, Florida
NCT05741242Enrolling by invitation· Phase 1/Phase 2
Vaccine trial using customized immune targets for solid tumors

This trial tests a personalized cancer vaccine made from synthetic long peptide “neoantigens,” aiming to be safe and help the immune system fight certain solid tumors. It may fit people with pancreatic cancer after starting first-line chemotherapy, and some other solid tumors with limited options.

Beverly Hills, California
NCT07182435Not yet recruiting· Early Phase 1
Personalized mRNA vaccine for advanced solid tumors

This trial tests a personalized mRNA cancer vaccine (RH125) for people with advanced solid tumors that have spread or cannot be removed by surgery. It may be an option if standard treatments have stopped working or are not suitable, and for some, it will be given with a PD-1 blocker.

Shenzhen, Guangdong
NCT05098210Recruiting· Phase 1
Personalized vaccine made from your tumor’s new immune targets

This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.

Seattle, Washington
NCT06682117Recruiting
A study of a personalized vaccine for advanced solid tumors

This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.

Shanghai, Shanghai Municipality

Hear when a new Muscle-Invasive Bladder Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.